| Symbol | FULC |
|---|---|
| Name | FULCRUM THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 26 LANDSDOWNE STREET, CAMBRIDGE, Massachusetts, 02139, United States |
| Telephone | +1 617 651-8851 |
| Fax | — |
| — | |
| Website | https://www.fulcrumtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001680581 |
| Description | Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0000070858-26-000396 <b>Size:</b> 171 KB
Read moreTANG KEVIN 🟢 acquired 167.6K shares of Fulcrum Therapeutics, Inc. (FULC) at $3.56 Transaction Date: Jul 16, 2026 | Filing ID: 000016
Read moreTANG KEVIN 🟢 acquired 249.9K shares of Fulcrum Therapeutics, Inc. (FULC) at $3.58 Transaction Date: Jul 13, 2026 | Filing ID: 000014
Read moreNew Form SCHEDULE 13G/A - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001214659-26-008613 <b>Size:</b> 14 KB
Read moreNew Form 3 - Fulcrum Therapeutics, Inc. <b>Filed:</b> 2026-07-15 <b>AccNo:</b> 0001178579-26-000013 <b>Size:</b> 6 KB
Read moreDorton Katina 🟢 acquired 32.0K shares (1 derivative) of Fulcrum Therapeutics, Inc. (FULC) at $3.66 Transaction Date: Jun 30, 2026 | Filing ID: 294699
Read moreGould Robert J 🟢 acquired 32.0K shares (1 derivative) of Fulcrum Therapeutics, Inc. (FULC) at $3.66 Transaction Date: Jun 30, 2026 | Filing ID: 294697
Read moreHaviland Kate 🟢 acquired 32.0K shares (1 derivative) of Fulcrum Therapeutics, Inc. (FULC) at $3.66 Transaction Date: Jun 30, 2026 | Filing ID: 294692
Read moreKing Rachel K. 🟢 acquired 32.0K shares (1 derivative) of Fulcrum Therapeutics, Inc. (FULC) at $3.66 Transaction Date: Jun 30, 2026 | Filing ID: 294691
Read moreGERAGHTY JAMES A 🟢 acquired 32.0K shares (1 derivative) of Fulcrum Therapeutics, Inc. (FULC) at $3.66 Transaction Date: Jun 30, 2026 | Filing ID: 294690
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07401823 | Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Phase2 | Sickle Cell Disease | Enrolling_By_Invitation | 2026-03-30 | 2030-07-05 | ClinicalTrials.gov |
| NCT07431398 | Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Dise… | Phase1 | Sickle Cell Disease | Terminated | 2025-12-13 | 2026-06-01 | ClinicalTrials.gov |
| NCT05397470 | Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohum… | Phase3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Terminated | 2022-06-16 | 2024-11-19 | ClinicalTrials.gov |
| NCT05169580 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir | Phase1 | Sickle Cell Disease | Completed | 2021-12-13 | 2026-01-20 | ClinicalTrials.gov |
| NCT05002231 | Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets | Phase1 | Healthy Adult Subjects | Completed | 2021-08-19 | 2021-10-22 | ClinicalTrials.gov |
| NCT04586985 | Safety, Tolerability and Pharmacokinetics of FTX-6058 | Phase1 | Healthy Adult Subjects | Completed | 2020-10-26 | 2022-11-15 | ClinicalTrials.gov |
| NCT04511819 | Losmapimod Safety and Efficacy in COVID-19 | Phase3 | COVID-19 | Terminated | 2020-08-28 | 2021-03-31 | ClinicalTrials.gov |
| NCT04264442 | Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral… | Phase2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Terminated | 2020-02-13 | 2024-11-07 | ClinicalTrials.gov |
| NCT04004000 | Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outco… | Phase2 | Facioscapulohumeral Muscular Dystrophy 1 | Terminated | 2019-08-23 | 2024-10-31 | ClinicalTrials.gov |
| NCT04003974 | Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular… | Phase2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Completed | 2019-08-09 | 2021-01-28 | ClinicalTrials.gov |
| NCT00859716 | ACE393-103 Vaccination Challenge Study | Phase2 | Campylobacter Infection | Unknown | 2008-10-01 | 2009-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Pociredir | Other | Phase PHASE1 | Sickle Cell Disease | TERMINATED | NCT07431398 |
| Placebo oral tablet | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT04003974 |
| Losmapimod oral tablet | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED | NCT04003974 |
| Placebo vaccine | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| ACE393 | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| Placebo vaccine | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| ACE393 | Other | Phase PHASE2 | Campylobacter Infection | UNKNOWN | NCT00859716 |
| Losmapimod one 15 mg oral tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05002231 |
| Losmapimod two 7.5 mg oral tablets | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05002231 |
| Losmapimod 15 mg oral tablet | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT05002231 |
| FTX-6058 / Midazolam Syrup | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04586985 |
| FTX-6058 - Two Dosing Periods | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04586985 |
| FTX-6058/placebo oral capsule(s) | Other | Phase PHASE1 | Healthy Adult Subjects | COMPLETED | NCT04586985 |
| Placebo oral tablet | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04511819 |
| Losmapimod oral tablet | Other | Phase PHASE3 | COVID-19 | TERMINATED | NCT04511819 |
| Losmapimod | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | NCT04264442 |
| Placebo oral tablet | Other | Phase PHASE3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | NCT05397470 |
| Losmapimod | Other | Phase PHASE3 | Facioscapulohumeral Muscular Dystrophy (FSHD) | TERMINATED | NCT05397470 |
| Losmapimod | Other | Phase PHASE2 | Facioscapulohumeral Muscular Dystrophy 1 | TERMINATED | NCT04004000 |
| Pociredir oral capsule(s) | Other | Phase PHASE1 | Sickle Cell Disease | COMPLETED | NCT05169580 |
| Pociredir | Other | Phase PHASE1 | Sickle Cell Disease | RECRUITING | NCT07431398 |
| Pociredir | Other | Phase PHASE2 | Sickle Cell Disease | ENROLLING_BY_INVITATION | NCT07401823 |